Biotech Proteintech Welcomes Dr. Deepa Shankar as Chief Scientific Officer
ROSEMONT, Ill.--(BUSINESS WIRE)--May 6, 2019--Proteintech, the benchmark in antibodies and proteins, welcomes Deepa Shankar, PhD, as the head of global Research and Development (R&D). She will be leading a team of over 150 scientists in the R&D and technological operations in the company. Besides accelerating Proteintech’s growth of their antibody and protein portfolio, she will also oversee the technological development of its products for clinical and pharmaceutical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005504/en/
Dr. Deepa Shankar, Proteintech Chief Scientific Officer (Photo: Business Wire)
She comes to Proteintech with 18 years of experience in a Scientific Director role. At Thermo Fisher Scientific, she served as Director of R&D and Head of R&D and Manufacturing in South Asia. Prior to joining Thermo Fisher, Dr. Shankar managed 11 oncology programs as Associate Director of the Oncology Therapeutics Group at the drug discovery company, Jubilant Life Sciences, in collaboration with Eli Lilly and Company.
“Dr. Shankar’s significant experience in biotech and pharma R&D is a great addition to our team,” says Proteintech CEO Jason Li, “Our goal is to help scientists read the Book of Life and her leadership at Proteintech will allow scientists all over the world to read many more chapters.”
“I am really happy to join this organization at this exciting time. The Company Culture is very inspiring and I am looking forward to leveraging my past knowledge and learning from the team to fuel the forward trajectory of the organization,” says new Proteintech CSO Deepa Shankar.
Deepa received her Ph.D. in molecular biology and immunology at the University of Southern California in Los Angeles receiving several awards and accolades like the Heidelberger Award for Cancer Research, U.C. Chancellor’s research award and the Boyer-Parvin award. During her postdoctoral work, she had opportunities to work with pharmaceutical companies gaining exposure to clinical research industry due to her strong passion for biology and her focus on cancer research later developing clinically-tested disease models for leukemia. Her experience in R&D, manufacturing, strategy and innovation will be a huge advantage to Proteintech as it continues optimizing and expanding product lines. An added benefit to Proteintech is her familiarity in transitional periods and acquisition integration within a company.
About Proteintech Group
Proteintech is an antibody manufacturer selling directly to scientists and only selling its own products to maintain the highest level of quality control leading to superior reproducibility and lot consistency. With over 2/3 of the human genome completed, we have a catalog of over 12,000 antibodies against 12,000 targets covering almost complete spectrum of research areas. With its acquisition of Humanzyme, Proteintech now offers the Humankine product line of animal-free human-cell expressed proteins. To view tens of thousands of publications and in-house validation images in WB, IHC, IF, FC, IP, CHIP, Knock-down siRNA using our antibodies and to learn more about Proteintech and their mission to deliver products directly from their bench to the researcher’s bench, please visit www.ptglab.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005504/en/
CONTACT: Proteintech Group, Inc.
KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS RESEARCH SCIENCE
Copyright Business Wire 2019.
PUB: 05/06/2019 11:29 AM/DISC: 05/06/2019 11:29 AM